| AOP Identifier | AOP Title | AO Classification | OECD Status | Taxonomic applicability | Coverage Score ⓘ The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints. | KE Identifier | KE Name |
|---|---|---|---|---|---|---|---|
| AOP:15 | Alkylation of DNA in male pre-meiotic germ cells leading to heritable mutations | Genetic disease | WPHA/WNT Endorsed | Mus musculus, Drosophila melanogaster, Oryzias latipes, Syrian golden hamster | 0.25 | KE:155 | Inadequate DNA repair |
| AOP:23 | Androgen receptor agonism leading to reproductive dysfunction (in repeat-spawning fish) | Unclassified | WPHA/WNT Endorsed | Pimephales promelas | 0.2 | KE:274 | Reduction, Testosterone synthesis by ovarian theca cells |
| KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells | ||||||
| AOP:25 | Aromatase inhibition leading to reproductive dysfunction | Unclassified | WPHA/WNT Endorsed | Fathead minnow, Medaka, Zebrafish | 0.12 | KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells |
| AOP:27 | Cholestatic Liver Injury induced by Inhibition of the Bile Salt Export Pump (ABCB11) | Gastrointestinal system disease | Under Development | Humans | 0.38 | KE:149 | Increase, Inflammation |
| KE:288 | Activation of specific nuclear receptors, Transcriptional change | ||||||
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:39 | Covalent Binding, Protein, leading to Increase, Allergic Respiratory Hypersensitivity Response | Respiratory system disease | Under Development | Human, Mouse | 0.2 | KE:272 | Activation/Proliferation, T-cells |
| AOP:40 | Covalent Protein binding leading to Skin Sensitisation | Integumentary system disease | WPHA/WNT Endorsed | Mouse, Human | 0.2 | KE:272 | Activation/Proliferation, T-cells |
| AOP:41 | Sustained AhR Activation leading to Rodent Liver Tumours | Cancer; Gastrointestinal system disease | Under Review | Rattus sp. ABTC 42503, Mus sp. 2000082 | 0.6 | KE:854 | Alterations, Cellular proliferation / hyperplasia |
| KE:853 | Changes/Inhibition, Cellular Homeostasis and Apoptosis | ||||||
| KE:139 | N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects | ||||||
| AOP:58 | NR1I3 (CAR) suppression leading to hepatic steatosis | Gastrointestinal system disease; Inherited metabolic disorder | - | Human, Mouse, Rat | 0.06 | KE:454 | Increased, Triglyceride formation |
| AOP:69 | Modulation of Adult Leydig Cell Function Subsequent to Decreased Cholesterol Synthesis or Transport in the Adult Leydig Cell | Reproductive system disease | - | Rattus norvegicus, Homo sapiens | 0.2 | KE:645 | Decreased Cholesterol, Decreased Testosterone Production by Adult Leydig Cells |
| AOP:73 | Xenobiotic Inhibition of Dopamine-beta-Hydroxylase and subsequent reduced fecundity | Unclassified | - | 0.15 | KE:10059 | Decreased LH surge for 24 hours | |
| KE:531 | Decreased, LH Surge | ||||||
| AOP:77 | Nicotinic acetylcholine receptor activation contributes to abnormal foraging and leads to colony death/failure 1 | Unclassified | - | Honey bee | 0.14 | KE:341 | Impairment, Learning and memory |
| AOP:78 | Nicotinic acetylcholine receptor activation contributes to abnormal role change within the worker bee caste leading to colony death failure 1 | Unclassified | - | Honey bee | 0.12 | KE:341 | Impairment, Learning and memory |
| AOP:80 | Nicotinic acetylcholine receptor activation contributes to accumulation of damaged mitochondrial DNA and leads to colony loss/failure | Unclassified | - | Honey bee | 0.12 | KE:664 | Overwhelmed, Mitochondrial DNA repair mechanisms |
| AOP:87 | Nicotinic acetylcholine receptor activation contributes to abnormal foraging and leads to colony loss/failure | Unclassified | - | Honey bee | 0.12 | KE:341 | Impairment, Learning and memory |
| AOP:88 | Nicotinic acetylcholine receptor activation contributes to abnormal foraging and leads to colony loss/failure via abnormal role change within caste | Unclassified | - | Honey bee | 0.14 | KE:341 | Impairment, Learning and memory |
| AOP:89 | Nicotinic acetylcholine receptor activation followed by desensitization contributes to abnormal foraging and directly leads to colony loss/failure | Unclassified | - | Honey bee | 0.12 | KE:341 | Impairment, Learning and memory |
| AOP:90 | Nicotinic acetylcholine receptor activation contributes to abnormal roll change within the worker bee caste leading to colony loss/failure 2 | Unclassified | - | Honey bee | 0.12 | KE:341 | Impairment, Learning and memory |
| AOP:109 | Cytotoxicity leading to bronchioloalveolar adenomas and carcinomas (in mouse) | Cancer; Respiratory system disease | - | Mus musculus | 0.2 | KE:734 | Increase, Regenerative cell proliferation (terminal bronchiolar epithelial cells) |
| AOP:110 | Inhibition of iodide pump activity leading to follicular cell adenomas and carcinomas (in rat and mouse) | Cancer; Endocrine system disease | - | Rattus norvegicus, Mus musculus | 0.29 | KE:1023 | Increased, Thyroid-stimulating hormone (TSH) |
| KE:739 | Increase, Hypertrophy and proliferation (follicular cell) | ||||||
| AOP:114 | HPPD inhibition leading to corneal papillomas and carcinomas (in rat) | Cancer | - | Rattus norvegicus | 0.17 | KE:778 | Increase, Regenerative cell proliferation (corneal cells) |
| AOP:115 | Epithelial cytotoxicity leading to forestomach tumors (in mouse and rat) | Cancer | - | Mus musculus, Rattus norvegicus | 0.4 | KE:149 | Increase, Inflammation |
| KE:781 | Increase, Regenerative cell proliferation (forestomach epithelial cells) | ||||||
| AOP:120 | Inhibition of 5α-reductase leading to Leydig cell tumors (in rat) | Cancer; Reproductive system disease | - | Rattus norvegicus, Mus musculus | 0.4 | KE:791 | Increased, Leutinizing hormone (LH) |
| KE:1690 | Decrease, circulating testosterone levels | ||||||
| AOP:121 | Urinary bladder calculi leading to urothelial papillomas and carcinomas (in mouse and rat) | Cancer; Urinary system disease | - | Mus musculus, Rattus norvegicus | 0.4 | KE:795 | Increase, Regenerative cell proliferation (urothelial cells) |
| KE:796 | Increase, Hyperplasia (urothelial) | ||||||
| AOP:122 | Prolyl hydroxylase inhibition leading to reproductive dysfunction via increased HIF1 heterodimer formation | Unclassified | - | Pimephales promelas | 0.1 | KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells |
| AOP:123 | Unknown MIE leading to reproductive dysfunction via increased HIF-1alpha transcription | Unclassified | - | Pimephales promelas | 0.09 | KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells |
| AOP:126 | Alpha-noradrenergic antagonism leads to reduced fecundity via delayed ovulation | Unclassified | - | 0.15 | KE:10059 | Decreased LH surge for 24 hours | |
| KE:531 | Decreased, LH Surge | ||||||
| AOP:128 | Kidney dysfunction by decreased thyroid hormone | Urinary system disease | Under Development | Sprague-Dawley, Homo sapiens | 0.09 | KE:825 | Decreased, Renal ability to dilute urine |
| AOP:136 | Intracellular Acidification Induced Olfactory Epithelial Injury Leading to Site of Contact Nasal Tumors | Benign neoplasm; Respiratory system disease | Under Review | 0.29 | KE:868 | Increase, Tissue Degeneration, Necrosis & Atrophy | |
| KE:870 | Increase, Cell Proliferation | ||||||
| AOP:164 | Beta-2 adrenergic agonist activity leading to mesovarian leiomyomas in the rat and mouse | Cancer; Reproductive system disease | - | CD-1 mouse, SD rat | 0.17 | KE:1042 | Proliferation/Clonal Expansion, smooth muscle |
| AOP:190 | Type II iodothyronine deiodinase (DIO2) inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.33 | KE:1023 | Increased, Thyroid-stimulating hormone (TSH) |
| KE:1829 | Altered, Thyroid hormone-dependent gene expression | ||||||
| AOP:191 | Type III iodotyrosine deiodinase (DIO3) inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.5 | KE:1154 | Increased, Triiodothyronine (T3) in tissues |
| KE:1829 | Altered, Thyroid hormone-dependent gene expression | ||||||
| AOP:195 | 5-hydroxytryptamine transporter (5-HTT) inhibition leading to population increase | Unclassified | - | Argopecten irradians, Mercenaria mercenaria, Arctica islandica, Spisula solidissima, Anodonta cygnea, Dreissena polymorpha | 0.12 | KE:1163 | Increased, Reproductive Success |
| AOP:196 | Volatile Organic Chemicals Activate TRPA1 Receptor to Induce Sensory Pulmonary Irritation | Respiratory system disease | - | 0.11 | KE:1218 | Opening of calcium channel, Calcium influx | |
| AOP:206 | Peroxisome proliferator-activated receptors γ inactivation leading to lung fibrosis | Musculoskeletal system disease; Respiratory system disease | Under Development | Homo sapiens | 0.17 | KE:149 | Increase, Inflammation |
| AOP:209 | Perturbation of cholesterol and glutathione homeostasis leading to hepatotoxicity: Integrated multi-OMICS approach for building AOP | Gastrointestinal system disease | - | 0.12 | KE:1289 | Perturbation of cholesterol | |
| AOP:213 | Inhibition of fatty acid beta oxidation leading to nonalcoholic steatohepatitis (NASH) | Gastrointestinal system disease; Inherited metabolic disorder | - | Vertebrates | 0.17 | KE:1115 | Increase, Reactive oxygen species |
| AOP:218 | Inhibition of CYP7B activity leads to decreased reproductive success via decreased locomotor activity | Unclassified | - | Japanese quail, Cynops pyrrhogaster | 0.17 | KE:1141 | Decreased, Reproductive Success |
| AOP:219 | Inhibition of CYP7B activity leads to decreased reproductive success via decreased sexual behavior | Unclassified | - | Japanese quail, Cynops pyrrhogaster | 0.33 | KE:1390 | Sexual behavior, decreased |
| KE:1141 | Decreased, Reproductive Success | ||||||
| AOP:245 | Reduction in photophosphorylation leading to growth inhibition in aquatic plants | Unclassified | - | Lemna minor, Lemna gibba | 0.09 | KE:40 | Decrease, Mitochondrial ATP production |
| AOP:258 | Renal protein alkylation leading to kidney toxicity | Urinary system disease | Under Development | Human, Rat, Mouse | 0.2 | KE:40 | Decrease, Mitochondrial ATP production |
| AOP:260 | CYP2E1 activation and formation of protein adducts leading to neurodegeneration | Nervous system disease | - | Human | 0.14 | KE:1392 | Oxidative Stress |
| AOP:263 | Uncoupling of oxidative phosphorylation leading to growth inhibition via decreased cell proliferation | Unclassified | WPHA/WNT Endorsed | Zebrafish, Mouse, Rat, Lemna minor, Human, Caenorhabditis elegans | 0.5 | KE:1821 | Decrease, Cell proliferation |
| KE:1771 | Decrease, Adenosine triphosphate pool | ||||||
| AOP:264 | Uncoupling of oxidative phosphorylation leading to growth inhibition via ATP depletion associated cell death | Unclassified | Under Development | 0.25 | KE:1771 | Decrease, Adenosine triphosphate pool | |
| AOP:265 | Uncoupling of oxidative phosphorylation leading to growth inhibition via increased cytosolic calcium | Unclassified | Under Development | 0.25 | KE:2064 | Increase, Cytosolic calcium | |
| AOP:266 | Uncoupling of oxidative phosphorylation leading to growth inhibition via decreased Na-K ATPase activity | Unclassified | Under Development | 0.17 | KE:1771 | Decrease, Adenosine triphosphate pool | |
| AOP:267 | Uncoupling of oxidative phosphorylation leading to growth inhibition via glucose depletion | Unclassified | Under Development | 0.2 | KE:1821 | Decrease, Cell proliferation | |
| AOP:272 | Deposition of energy leading to lung cancer | Cancer | WPHA/WNT Endorsed | Human, Rat, Mouse | 0.29 | KE:155 | Inadequate DNA repair |
| KE:870 | Increase, Cell Proliferation | ||||||
| AOP:274 | Histone deacetylase inhibition leads to impeded craniofacial development | Musculoskeletal system disease | - | 0.25 | KE:1558 | Collagen production, reduced | |
| AOP:275 | Histone deacetylase inhibition leads to neural tube defects | Neural tube defect | - | 0.2 | KE:1560 | Altered differentiation | |
| AOP:280 | α-diketone-induced bronchiolitis obliterans | Musculoskeletal system disease; Respiratory system disease | - | 0.14 | KE:149 | Increase, Inflammation | |
| AOP:286 | Mitochondrial complex III antagonism leading to growth inhibition (1) | Unclassified | - | Lemna minor, Daphnia magna, Danio rerio | 0.5 | KE:1821 | Decrease, Cell proliferation |
| KE:1771 | Decrease, Adenosine triphosphate pool | ||||||
| AOP:287 | Mitochondrial complex III antagonism leading to growth inhibition (2) | Unclassified | - | Lemna minor, Daphnia magna, Danio rerio | 0.5 | KE:1771 | Decrease, Adenosine triphosphate pool |
| KE:1825 | Increase, Cell death | ||||||
| AOP:290 | Mitochondrial ATP synthase antagonism leading to growth inhibition (1) | Unclassified | - | Daphnia magna | 0.5 | KE:1821 | Decrease, Cell proliferation |
| KE:1771 | Decrease, Adenosine triphosphate pool | ||||||
| AOP:291 | Mitochondrial ATP synthase antagonism leading to growth inhibition (2) | Unclassified | - | Daphnia magna | 0.5 | KE:1771 | Decrease, Adenosine triphosphate pool |
| KE:1825 | Increase, Cell death | ||||||
| AOP:296 | Oxidative DNA damage leading to chromosomal aberrations and mutations | Genetic disease; Chromosomal disease | WPHA/WNT Endorsed | Human, Mice, Rat, Fish | 0.2 | KE:155 | Inadequate DNA repair |
| AOP:299 | Deposition of energy leading to population decline via DNA oxidation and follicular atresia | Unclassified | - | 0.14 | KE:1115 | Increase, Reactive oxygen species | |
| AOP:303 | Frustrated phagocytosis-induced lung cancer | Cancer | Under Development | Mammals | 0.29 | KE:870 | Increase, Cell Proliferation |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:305 | 5α-reductase inhibition leading to short anogenital distance (AGD) in male (mammalian) offspring | Unclassified | Under Development | Rat, Human, Mouse | 0.2 | KE:1614 | Decrease, androgen receptor activation |
| AOP:309 | Luteinizing hormone receptor antagonism leading to reproductive dysfunction | Unclassified | - | Fish | 0.14 | KE:1695 | Impaired ovulation |
| AOP:310 | Embryonic Activation of the AHR leading to Reproductive failure, via epigenetic down-regulation of GnRHR | Unclassified | - | Zebrafish | 0.08 | KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells |
| AOP:311 | Deposition of energy leading to population decline via DNA oxidation and oocyte apoptosis | Unclassified | - | Daphnia magna, Fish | 0.14 | KE:1115 | Increase, Reactive oxygen species |
| AOP:318 | Glucocorticoid Receptor activation leading to hepatic steatosis | Gastrointestinal system disease; Inherited metabolic disorder | - | 0.2 | KE:291 | Accumulation, Triglyceride | |
| AOP:321 | Reduced environmental pH leading to thinner shells in Mytilus edulis | Unclassified | - | 0.18 | KE:592 | Reduced, survival | |
| KE:10042 | Abnormal development | ||||||
| AOP:334 | Glucocorticoid Receptor Agonism Leading to Impaired Fin Regeneration | Unclassified | - | Teleost fish | 0.17 | KE:2245 | Altered Cell Differentiation Signaling |
| AOP:335 | AOP for urothelial carcinogenesis due to chemical cytotoxicity by mitochondrial impairment | Cancer; Urinary system disease | - | Rat | 0.4 | KE:795 | Increase, Regenerative cell proliferation (urothelial cells) |
| KE:796 | Increase, Hyperplasia (urothelial) | ||||||
| AOP:346 | Aromatase inhibition leads to male-biased sex ratio via impacts on gonad differentiation | Unclassified | WPHA/WNT Endorsed | Zebrafish, Oreochromis niloticus, Chinook salmon, Fathead minnow, European sea bass | 0.4 | KE:1789 | Reduction, 17beta-estradiol synthesis by the undifferentiated gonad |
| KE:1790 | Increased, Differentiation to Testis | ||||||
| AOP:348 | Inhibition of 11β-Hydroxysteroid Dehydrogenase leading to decreased population trajectory | Unclassified | Under Development | Fish | 0.4 | KE:1758 | Impaired, Spermatogenesis |
| KE:406 | decreased, Fertility | ||||||
| AOP:349 | Inhibition of 11β-hydroxylase leading to decresed population trajectory | Unclassified | Under Development | Fish | 0.38 | KE:1798 | Decreased spermatogenesis |
| KE:406 | decreased, Fertility | ||||||
| KE:1836 | Decreased plasma Cortisol level | ||||||
| AOP:362 | Immune mediated hepatitis | Gastrointestinal system disease; Immune system disease | - | Homo sapiens, Rat | 0.25 | KE:1817 | Apoptotic cell death |
| KE:1633 | Increase in inflammation | ||||||
| AOP:368 | Cytochrome oxidase inhibition leading to increased nasal lesions | Unclassified | - | Rodents, Human | 0.33 | KE:1825 | Increase, Cell death |
| AOP:376 | Androgen receptor agonism leading to male-biased sex ratio | Unclassified | WPHA/WNT Endorsed | Zebrafish, Medaka, Fathead minnow, Channel catfish, Oreochromis niloticus, Chinook salmon | 0.25 | KE:1790 | Increased, Differentiation to Testis |
| AOP:382 | Angiotensin II type 1 receptor (AT1R) agonism leading to lung fibrosis | Musculoskeletal system disease; Respiratory system disease | Under Development | 0.17 | KE:1115 | Increase, Reactive oxygen species | |
| AOP:383 | Inhibition of Angiotensin-converting enzyme 2 leading to liver fibrosis | Gastrointestinal system disease | Under Development | 0.17 | KE:1115 | Increase, Reactive oxygen species | |
| AOP:384 | Hyperactivation of ACE/Ang-II/AT1R axis leading to chronic kidney disease | Urinary system disease | - | 0.17 | KE:1115 | Increase, Reactive oxygen species | |
| AOP:386 | Deposition of ionizing energy leading to population decline via inhibition of photosynthesis | Reproductive system disease | - | Lemna minor, Chlamydomonas reinhardtii | 0.12 | KE:1115 | Increase, Reactive oxygen species |
| AOP:387 | Deposition of ionising energy leading to population decline via mitochondrial dysfunction | Reproductive system disease | - | Lemna minor | 0.25 | KE:1115 | Increase, Reactive oxygen species |
| KE:40 | Decrease, Mitochondrial ATP production | ||||||
| AOP:388 | Deposition of ionising energy leading to population decline via programmed cell death | Reproductive system disease | - | Lemna minor | 0.4 | KE:1194 | Increase, DNA damage |
| KE:1864 | Increase, Programmed cell death | ||||||
| AOP:397 | Bulky DNA adducts leading to mutations | Genetic disease | Under Development | 0.33 | KE:155 | Inadequate DNA repair | |
| AOP:399 | Inhibition of Fyna leading to increased mortality via decreased eye size (Microphthalmos) | Unclassified | - | Zebrafish | 0.12 | KE:1821 | Decrease, Cell proliferation |
| AOP:409 | Frustrated phagocytosis leads to malignant mesothelioma | Cancer | - | 0.38 | KE:870 | Increase, Cell Proliferation | |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:1896 | Genomic instability | ||||||
| AOP:410 | GSK3beta inactivation leading to increased mortality via defects in developing inner ear | Unclassified | - | Zebrafish | 0.1 | KE:1825 | Increase, Cell death |
| AOP:413 | Oxidation and antagonism of reduced glutathione leading to mortality via acute renal failure | Unclassified | - | Fish, Mice | 0.33 | KE:759 | Increased, Kidney Failure |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:414 | Aryl hydrocarbon receptor activation leading to lung fibrosis through TGF-β dependent fibrosis toxicity pathway | Musculoskeletal system disease; Respiratory system disease | - | 0.2 | KE:1920 | Altered gene expression, TGF-β dependent fibrosis pathway | |
| AOP:416 | Aryl hydrocarbon receptor activation leading to lung cancer through IL-6 toxicity pathway | Cancer | - | 0.17 | KE:1115 | Increase, Reactive oxygen species | |
| AOP:418 | Aryl hydrocarbon receptor activation leading to impaired lung function through AHR-ARNT toxicity pathway | Respiratory system disease | - | 0.4 | KE:1825 | Increase, Cell death | |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:419 | Aryl hydrocarbon receptor activation leading to impaired lung function through P53 toxicity pathway | Respiratory system disease | - | 0.5 | KE:1923 | Altered gene expression, P53 dependent apoptosis pathway | |
| KE:1262 | Apoptosis | ||||||
| AOP:420 | Aryl hydrocarbon receptor activation leading to lung cancer through sustained NRF2 toxicity pathway | Cancer | - | 0.5 | KE:1917 | Altered gene expression, NRF2 dependent antioxidant pathway | |
| KE:870 | Increase, Cell Proliferation | ||||||
| AOP:431 | Increased tumor necrosis factor (TNF) leading to increased risk of gestational diabetes mellitus (GDM) | Inherited metabolic disorder | - | Human | 0.2 | KE:1952 | Abnormal, Glucose homeostasis |
| AOP:432 | Deposition of Energy by Ionizing Radiation leading to Acute Myeloid Leukemia | Hematopoietic system disease; Cancer | - | Homo sapiens, Mus musculus | 0.27 | KE:1194 | Increase, DNA damage |
| KE:155 | Inadequate DNA repair | ||||||
| KE:870 | Increase, Cell Proliferation | ||||||
| AOP:435 | Deposition of ionising energy leads to population decline via pollen abnormal | Reproductive system disease | - | 0.17 | KE:1194 | Increase, DNA damage | |
| AOP:437 | Inhibition of mitochondrial electron transport chain (ETC) complexes leading to kidney toxicity | Urinary system disease | Under Development | 0.2 | KE:1392 | Oxidative Stress | |
| AOP:441 | Ionizing radiation-induced DNA damage leads to microcephaly via apoptosis and premature cell differentiation | Congenital nervous system abnormality; Nervous system disease | - | Homo sapiens, Mus musculus musculus, Rattus norvegicus | 0.43 | KE:1194 | Increase, DNA damage |
| KE:1974 | Activation of Tumor Protein 53 | ||||||
| KE:1262 | Apoptosis | ||||||
| AOP:451 | Interaction with lung resident cell membrane components leads to lung cancer | Cancer | - | Human | 0.22 | KE:870 | Increase, Cell Proliferation |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:452 | Adverse outcome pathway of PM-induced respiratory toxicity | Respiratory system disease | - | 0.18 | KE:1392 | Oxidative Stress | |
| KE:1262 | Apoptosis | ||||||
| AOP:457 | Succinate dehydrogenase inhibition leading to increased insulin resistance through reduction in circulating thyroxine | Inherited metabolic disorder | - | Human | 0.17 | KE:1392 | Oxidative Stress |
| AOP:460 | Antagonism of Smoothened receptor leading to orofacial clefting | Unclassified | Under Development | Mouse | 0.22 | KE:1821 | Decrease, Cell proliferation |
| KE:1262 | Apoptosis | ||||||
| AOP:464 | Calcium overload in dopaminergic neurons of the substantia nigra leading to parkinsonian motor deficits | Nervous system disease | - | 0.16 | KE:1392 | Oxidative Stress | |
| KE:1825 | Increase, Cell death | ||||||
| KE:389 | Increased, Intracellular Calcium overload | ||||||
| AOP:465 | Alcohol dehydrogenase leading to reproductive dysfunction | Unclassified | - | 0.25 | KE:748 | Increased, Estrogen receptor (ER) activity | |
| KE:2050 | Increase, developmental abnormalities | ||||||
| AOP:467 | Knickkopf leading to mortality | Unclassified | - | 0.11 | KE:2050 | Increase, developmental abnormalities | |
| AOP:470 | Deposition of energy leads to abnormal vascular remodeling | Cardiovascular system disease | Under Review | Human, Rat, Mouse, Rabbit | 0.25 | KE:1392 | Oxidative Stress |
| KE:2244 | Altered Stress Response Signaling | ||||||
| AOP:478 | Deposition of energy leading to occurrence of cataracts | Nervous system disease; Monogenic disease | Under Review | Human, Mouse, Rat, Rhesus monkeys, Rabbit, Guinea pig | 0.3 | KE:1392 | Oxidative Stress |
| KE:155 | Inadequate DNA repair | ||||||
| KE:870 | Increase, Cell Proliferation | ||||||
| AOP:479 | Mitochondrial complexes inhibition leading to left ventricular function decrease via increased myocardial oxidative stress | Cardiovascular system disease; Thoracic disease | Under Development | 0.14 | KE:1392 | Oxidative Stress | |
| AOP:480 | Mitochondrial complexes inhibition leading to heart failure via decreased ATP production | Cardiovascular system disease; Thoracic disease | Under Development | 0.2 | KE:40 | Decrease, Mitochondrial ATP production | |
| AOP:482 | Deposition of energy leading to occurrence of bone loss | Musculoskeletal system disease | Under Review | Human, Mouse, Rat, Rhesus monkeys | 0.43 | KE:1392 | Oxidative Stress |
| KE:1825 | Increase, Cell death | ||||||
| KE:2245 | Altered Cell Differentiation Signaling | ||||||
| AOP:491 | Decrease, GLI1/2 target gene expression leads to orofacial clefting | Unclassified | Under Development | Mouse | 0.33 | KE:1821 | Decrease, Cell proliferation |
| KE:1262 | Apoptosis | ||||||
| AOP:495 | Androgen receptor activation leading to prostate cancer | Reproductive system disease; Cancer | - | 0.22 | KE:854 | Alterations, Cellular proliferation / hyperplasia | |
| KE:1183 | Decreased, Apoptosis (Epithelial Cells) | ||||||
| AOP:496 | Androgen receptor agonism leading to reproduction dysfunction (in zebrafish) | Unclassified | - | Zebrafish | 0.1 | KE:1690 | Decrease, circulating testosterone levels |
| AOP:510 | Demethylation of PPAR promotor leading to vascular disrupting effects | Cardiovascular system disease | - | Human, Mouse, Zebrafish | 0.1 | KE:1392 | Oxidative Stress |
| AOP:518 | Liver X Receptor (LXR) activation leads to liver steatosis | Gastrointestinal system disease; Inherited metabolic disorder | - | Vertebrates | 0.2 | KE:291 | Accumulation, Triglyceride |
| AOP:524 | Gluten-driven immune activation leading to celiac disease in genetically predisposed individuals | Immune system disease; Gastrointestinal system disease | - | Human | 0.11 | KE:2255 | Innate immune response, activation |
| AOP:529 | Perfluorooctanesulfonic acid (PFOS) binding to peroxisome proliferator-activated receptors (PPARs) causes dysregulation of lipid metabolism and subsequent liver steatosis | Gastrointestinal system disease; Inherited metabolic disorder | - | Vertebrates, Mouse, Rat, Zebrafish | 0.12 | KE:291 | Accumulation, Triglyceride |
| AOP:544 | Inhibition of neuropathy target esterase leading to delayed neuropathy via increased inflammation | Nervous system disease | - | Homo sapiens, Mus musculus | 0.17 | KE:149 | Increase, Inflammation |
| AOP:563 | Aryl hydrocarbon Receptor (AHR) activation causes Premature Ovarian Insufficiency via Bax mediated apoptosis | Reproductive system disease; Endocrine system disease | - | Rat, Mouse, Zebra fish, Human | 0.17 | KE:1262 | Apoptosis |
| AOP:564 | DBDPE-induced inhibition of mitochondrial complex Ⅰ leading to population decline via neurotoxicity and metabotoxicity. | Unclassified | - | Zebrafish | 0.18 | KE:2301 | Abnormal, Behavior |
| KE:40 | Decrease, Mitochondrial ATP production | ||||||
| AOP:573 | Inhibition, cytochrome oxidase leads to Increased, pulmonary edema | Respiratory system disease | - | Rodents, Humans | 0.33 | KE:1825 | Increase, Cell death |
| AOP:574 | Inhibition, cytochrome oxidase leads to Loss of olfactory function | Unclassified | - | Rodents, Humans | 0.33 | KE:1825 | Increase, Cell death |
| AOP Identifier | AOP Title | AO Classification | OECD Status | Taxonomic applicability | Coverage Score ⓘ The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints. | KE Identifier | KE Name |
|---|---|---|---|---|---|---|---|
| AOP:6 | Antagonist binding to PPARα leading to body-weight loss | Symptom | WPHA/WNT Endorsed | Mus musculus, Homo sapiens, Pimephales promelas, Colinus virginianus, Rattus norvegicus | 0.12 | KE:864 | Decreased, Body Weight |
| AOP:7 | Aromatase (Cyp19a1) reduction leading to impaired fertility in adult female | Reproductive system disease; Endocrine system disease; Reproductive system disease | Under Review | Rat, Mouse, Human | 0.4 | KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells |
| KE:406 | decreased, Fertility | ||||||
| AOP:12 | Chronic binding of antagonist to N-methyl-D-aspartate receptors (NMDARs) during brain development leads to neurodegeneration with impairment in learning and memory in aging | Nervous system disease; Developmental disorder of mental health | WPHA/WNT Endorsed | Monkey, Rat, Human, Mouse, Zebrafish | 0.25 | KE:52 | Decreased, Calcium influx |
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:13 | Chronic binding of antagonist to N-methyl-D-aspartate receptors (NMDARs) during brain development induces impairment of learning and memory abilities | Developmental disorder of mental health | WPHA/WNT Endorsed | Human, Mouse, Monkey sp., Rat | 0.2 | KE:52 | Decreased, Calcium influx |
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:17 | Binding of electrophilic chemicals to SH(thiol)-group of proteins and /or to seleno-proteins involved in protection against oxidative stress during brain development leads to impairment of learning and memory | Developmental disorder of mental health | WPHA/WNT Endorsed | Rat, Mouse, Human | 0.2 | KE:1392 | Oxidative Stress |
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:18 | PPARα activation in utero leading to impaired fertility in males | Reproductive system disease | Under Review | Human, Rat, Mouse | 0.5 | KE:289 | Decrease, Translocator protein (TSPO) |
| KE:413 | Reduction, Testosterone synthesis in Leydig cells | ||||||
| KE:1690 | Decrease, circulating testosterone levels | ||||||
| KE:406 | decreased, Fertility | ||||||
| AOP:21 | Aryl hydrocarbon receptor activation leading to early life stage mortality, via increased COX-2 | Unclassified | WPHA/WNT Endorsed | Zebrafish, Medaka, Gallus gallus | 0.4 | KE:317 | Altered, Cardiovascular development/function |
| KE:947 | Increase, Early Life Stage Mortality | ||||||
| AOP:34 | LXR activation leading to hepatic steatosis | Gastrointestinal system disease; Inherited metabolic disorder | - | 0.15 | KE:291 | Accumulation, Triglyceride | |
| KE:345 | N/A, Liver Steatosis | ||||||
| AOP:37 | PPARα activation leading to hepatocellular adenomas and carcinomas in rodents | Cancer; Gastrointestinal system disease | Under Development | Mouse, Rat | 0.4 | KE:716 | Increase, cell proliferation (hepatocytes) |
| KE:719 | Increase, hepatocellular adenomas and carcinomas | ||||||
| AOP:43 | Disruption of VEGFR Signaling Leading to Developmental Defects | Unclassified | WPHA/WNT Endorsed | Mouse, Zebrafish, Rats, Human | 0.2 | KE:1001 | Increased, Developmental Defects |
| AOP:48 | Binding of agonists to ionotropic glutamate receptors in adult brain causes excitotoxicity that mediates neuronal cell death, contributing to learning and memory impairment. | Developmental disorder of mental health | WPHA/WNT Endorsed | Human, Mouse, Rat | 0.22 | KE:389 | Increased, Intracellular Calcium overload |
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:54 | Inhibition of Na+/I- symporter (NIS) leads to learning and memory impairment | Developmental disorder of mental health | WPHA/WNT Endorsed | Homo sapiens, Rattus sp. | 0.1 | KE:341 | Impairment, Learning and memory |
| AOP:63 | Cyclooxygenase inhibition leading to reproductive dysfunction | Reproductive system disease | - | Goldfish, Human, Mouse, Rat | 0.4 | KE:675 | Reduced, Reproductive Success |
| KE:488 | Decrease, Ovulation | ||||||
| AOP:64 | Glucocorticoid Receptor (GR) Mediated Adult Leydig Cell Dysfunction Leading to Decreased Male Fertility | Reproductive system disease | - | Rattus norvegicus | 0.71 | KE:413 | Reduction, Testosterone synthesis in Leydig cells |
| KE:1690 | Decrease, circulating testosterone levels | ||||||
| KE:406 | decreased, Fertility | ||||||
| KE:520 | Decreased sperm quantity or quality in the adult, Decreased fertility | ||||||
| KE:496 | Increased apoptosis, decreased fetal/adult Leydig Cells | ||||||
| AOP:91 | Sodium channel inhibition leading to reduced survival | Unclassified | - | Medaka, Gammarus pulex, Hydra | 0.17 | KE:592 | Reduced, survival |
| AOP:95 | Ether-a-go-go (ERG) voltage-gated potassium channel inhibition leading to reduced survival | Unclassified | - | 0.17 | KE:592 | Reduced, survival | |
| AOP:99 | Histamine (H2) receptor antagonism leading to reduced survival | Unclassified | - | Zebrafish | 0.29 | KE:636 | Decreased, survival |
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:100 | Cyclooxygenase inhibition leading to reproductive dysfunction via inhibition of female spawning behavior | Reproductive system disease | - | Goldfish | 0.14 | KE:675 | Reduced, Reproductive Success |
| AOP:101 | Cyclooxygenase inhibition leading to reproductive dysfunction via inhibition of pheromone release | Reproductive system disease | - | Goldfish | 0.14 | KE:675 | Reduced, Reproductive Success |
| AOP:102 | Cyclooxygenase inhibition leading to reproductive dysfunction via interference with meiotic prophase I /metaphase I transition | Reproductive system disease | - | Goldfish, Human, Rat, Mouse | 0.2 | KE:690 | Reduced, Luteinizing hormone (LH), plasma |
| KE:675 | Reduced, Reproductive Success | ||||||
| AOP:103 | Cyclooxygenase inhibition leading to reproductive dysfunction via interference with spindle assembly checkpoint | Reproductive system disease | - | Goldfish, Human, Rat, Mouse | 0.2 | KE:690 | Reduced, Luteinizing hormone (LH), plasma |
| KE:675 | Reduced, Reproductive Success | ||||||
| AOP:105 | Alpha2u-microglobulin cytotoxicity leading to renal tubular adenomas and carcinomas (in male rat) | Cancer; Urinary system disease | - | Rattus norvegicus | 0.33 | KE:713 | Increase, Adenomas/carcinomas (renal tubular) |
| KE:710 | Increase, Regenerative cell proliferation (tubular epithelial cells) | ||||||
| AOP:107 | Constitutive androstane receptor activation leading to hepatocellular adenomas and carcinomas in the mouse and the rat | Cancer; Gastrointestinal system disease | Under Review | Rattus norvegicus, Mus musculus | 0.6 | KE:1214 | Altered gene expression specific to CAR activation, Hepatocytes |
| KE:719 | Increase, hepatocellular adenomas and carcinomas | ||||||
| KE:716 | Increase, cell proliferation (hepatocytes) | ||||||
| AOP:108 | Inhibition of pyruvate dehydrogenase kinase leading to hepatocellular adenomas and carcinomas (in mouse and rat) | Cancer; Gastrointestinal system disease | - | Mus musculus, Rattus norvegicus | 0.17 | KE:719 | Increase, hepatocellular adenomas and carcinomas |
| AOP:112 | Increased dopaminergic activity leading to endometrial adenocarcinomas (in Wistar rat) | Reproductive system disease; Cancer | - | Rattus norvegicus | 0.5 | KE:111 | Agonism, Estrogen receptor |
| KE:772 | Increase, Hyperplasia (glandular epithelial cells of endometrium) | ||||||
| KE:773 | Increase, Endometrial adenocarcinomas | ||||||
| AOP:116 | Cytotoxicity leading to renal tubular adenomas and carcinomas (in male rat) | Cancer; Urinary system disease | - | Rattus norvegicus | 0.5 | KE:713 | Increase, Adenomas/carcinomas (renal tubular) |
| KE:710 | Increase, Regenerative cell proliferation (tubular epithelial cells) | ||||||
| AOP:117 | Androgen receptor activation leading to hepatocellular adenomas and carcinomas (in mouse and rat) | Cancer; Gastrointestinal system disease | Under Development | Mus musculus, Rattus norvegicus | 0.5 | KE:716 | Increase, cell proliferation (hepatocytes) |
| KE:719 | Increase, hepatocellular adenomas and carcinomas | ||||||
| AOP:124 | HMG-CoA reductase inhibition leading to decreased fertility | Reproductive system disease | - | Rattus rattus | 0.5 | KE:807 | Decreased, cholesterol |
| KE:1690 | Decrease, circulating testosterone levels | ||||||
| KE:330 | Decrease, Fertility | ||||||
| AOP:134 | Sodium Iodide Symporter (NIS) Inhibition and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive disorder | - | Rat, Homo sapiens | 0.11 | KE:402 | Cognitive function, decreased |
| AOP:139 | Alkylation of DNA leading to cancer 1 | Cancer | - | Homo sapiens, Mus musculus | 0.5 | KE:885 | Increase, Cancer |
| KE:155 | Inadequate DNA repair | ||||||
| AOP:149 | Peptide Oxidation Leading to Hypertension | Cardiovascular system disease | Under Development | Human, Mouse, Rat, Cow | 0.1 | KE:952 | Hypertension |
| AOP:150 | Aryl hydrocarbon receptor activation leading to early life stage mortality, via reduced VEGF | Unclassified | WPHA/WNT Endorsed | Chicken, Zebrafish, Mouse, Rattus norvegicus | 0.29 | KE:317 | Altered, Cardiovascular development/function |
| KE:947 | Increase, Early Life Stage Mortality | ||||||
| AOP:151 | AhR activation leading to preeclampsia | Cardiovascular system disease | Under Development | Homo sapiens, Mus musculus | 0.14 | KE:1893 | increase, Preeclampsia |
| AOP:203 | 5-hydroxytryptamine transporter inhibition leading to decreased reproductive success and population decline | Reproductive system disease | - | 0.12 | KE:1141 | Decreased, Reproductive Success | |
| AOP:204 | 5-hydroxytryptamine transporter inhibition leading to increased reproductive success and population increase | Unclassified | - | 0.12 | KE:1163 | Increased, Reproductive Success | |
| AOP:205 | AOP from chemical insult to cell death | Unclassified | - | Vertebrates | 0.17 | KE:1262 | Apoptosis |
| AOP:207 | NADPH oxidase and P38 MAPK activation leading to reproductive failure in Caenorhabditis elegans | Reproductive system disease | - | Caenorhabditis elegans | 0.5 | KE:1115 | Increase, Reactive oxygen species |
| KE:1277 | Reproductive failure | ||||||
| KE:1281 | Increased, DNA Damage-Repair | ||||||
| KE:1262 | Apoptosis | ||||||
| AOP:212 | Histone deacetylase inhibition leading to testicular atrophy | Reproductive system disease | WPHA/WNT Endorsed | Rat, Human, Mouse | 0.5 | KE:1506 | Testicular atrophy |
| KE:1515 | Spermatocyte depletion | ||||||
| KE:1262 | Apoptosis | ||||||
| AOP:220 | Cyp2E1 Activation Leading to Liver Cancer | Cancer; Gastrointestinal system disease | WPHA/WNT Endorsed | Rodents, Homo sapiens | 0.6 | KE:1392 | Oxidative Stress |
| KE:1393 | Hepatocytotoxicity | ||||||
| KE:1395 | Liver Cancer | ||||||
| AOP:242 | Inhibition of lysyl oxidase leading to enhanced chronic fish toxicity | Unclassified | - | Fish | 0.12 | KE:636 | Decreased, survival |
| AOP:261 | L-type calcium channel blockade leading to heart failure via decrease in cardiac contractility | Cardiovascular system disease | Under Development | Vertebrates | 0.12 | KE:1535 | Heart failure |
| AOP:294 | Increased reactive oxygen and nitrogen species (RONS) leading to increased risk of breast cancer | Genetic disease; Thoracic disease; Cancer | Under Development | 0.33 | KE:1194 | Increase, DNA damage | |
| KE:1193 | N/A, Breast Cancer | ||||||
| KE:1182 | Increase, Cell Proliferation (Epithelial Cells) | ||||||
| AOP:304 | TBX1 inhibition leading to congenital cardiac conotruncal anomalies | Cardiovascular system disease | - | 0.17 | KE:1685 | Anomalies, Congenital cardiac conotruncal | |
| AOP:322 | Alkylation of DNA leading to reduced sperm count | Reproductive system disease | - | 0.6 | KE:155 | Inadequate DNA repair | |
| KE:1365 | Increase, Apoptosis | ||||||
| KE:1757 | Reduce, Sperm count | ||||||
| AOP:323 | PPARalpha Agonism Leading to Decreased Viable Offspring via Decreased 11-Ketotestosterone | Unclassified | - | Teleost fish | 0.5 | KE:807 | Decreased, cholesterol |
| KE:1758 | Impaired, Spermatogenesis | ||||||
| KE:2147 | Decreased, Viable Offspring | ||||||
| AOP:379 | Binding to ACE2 leading to thrombosis and disseminated intravascular coagulation | Cardiovascular system disease | Under Development | Homo sapiens | 0.14 | KE:1846 | Thrombosis and Disseminated Intravascular Coagulation |
| AOP:398 | Decreased ALDH1A (RALDH) activity leading to decreased fertility via disrupted meiotic initiation of fetal oogonia | Reproductive system disease | Under Development | Mouse, Rat, Human | 0.17 | KE:406 | decreased, Fertility |
| AOP:406 | SARS-CoV-2 infection leading to hyperinflammation | Unclassified | - | 0.17 | KE:1868 | Hyperinflammation | |
| AOP:439 | Activation of the AhR leading to metastatic breast cancer | Thoracic disease; Cancer | Under Development | Humans, Mice | 0.44 | KE:1982 | metastatic breast cancer |
| KE:1971 | Increased, tumor growth | ||||||
| KE:149 | Increase, Inflammation | ||||||
| KE:1262 | Apoptosis | ||||||
| AOP:442 | Binding to voltage gate sodium channels during development leads to cognitive impairment | Cognitive disorder | Under Review | Rattus norvegicus, Mouse, Humans | 0.14 | KE:402 | Cognitive function, decreased |
| AOP:443 | DNA damage and mutations leading to Metastatic Breast Cancer | Thoracic disease; Cancer | Under Development | Human and other cells in culture, Human, Mice, Rat, Canine heartworm nematode, Yeast | 0.3 | KE:1982 | metastatic breast cancer |
| KE:155 | Inadequate DNA repair | ||||||
| KE:112 | Antagonism, Estrogen receptor | ||||||
| AOP:455 | Aryl hydrocarbon receptor activation leading to early life stage mortality via sox9 repression induced impeded craniofacial development | Musculoskeletal system disease | Under Review | Zebrafish, Mouse, Human, Sebastiscus marmoratus, Salmo salar, Chicken | 0.17 | KE:947 | Increase, Early Life Stage Mortality |
| AOP:456 | Aryl hydrocarbon receptor activation leading to early life stage mortality via sox9 repression induced cardiovascular toxicity | Unclassified | Under Review | Zebrafish, Mouse, Human, Chicken | 0.33 | KE:317 | Altered, Cardiovascular development/function |
| KE:947 | Increase, Early Life Stage Mortality | ||||||
| AOP:458 | AhR activation in the liver leading to Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive disorder | - | Rat, Mouse, Monkey, Human | 0.12 | KE:402 | Cognitive function, decreased |
| AOP:459 | AhR activation in the thyroid leading to Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive disorder | - | Human, Mouse, Rat | 0.22 | KE:1392 | Oxidative Stress |
| KE:402 | Cognitive function, decreased | ||||||
| AOP:468 | Binding of SARS-CoV-2 to ACE2 leads to hyperinflammation (via cell death) | Unclassified | - | 0.25 | KE:1825 | Increase, Cell death | |
| KE:1868 | Hyperinflammation | ||||||
| AOP:474 | Succinate dehydrogenase inactivation leads to cancer by promoting EMT | Cancer | Under Development | Human and other cells in culture | 0.2 | KE:885 | Increase, Cancer |
| AOP:475 | Binding of chemicals to ionotropic glutamate receptors leads to impairment of learning and memory via loss of drebrin from dendritic spines of neurons | Developmental disorder of mental health | Under Development | Mouse, Rat, Human, Caenorhabditis elegans | 0.25 | KE:389 | Increased, Intracellular Calcium overload |
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:483 | Deposition of Energy Leading to Learning and Memory Impairment | Developmental disorder of mental health | Under Review | Mouse, Rat, Rabbit, Dog, Pigs, Cow, Human | 0.38 | KE:1392 | Oxidative Stress |
| KE:2244 | Altered Stress Response Signaling | ||||||
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:486 | Binding to the extracellular protein laminin leading to decreased cognitive function | Cognitive disorder | - | Human | 0.14 | KE:402 | Cognitive function, decreased |
| AOP:490 | Co-activation of IP3R and RyR leads to reduced IQ through non-cholinergic mechanisms | Developmental disorder of mental health | - | 0.18 | KE:2121 | decreased, Intellectual Quotient | |
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:492 | Glutathione conjugation leading to reproductive dysfunction via oxidative stress | Reproductive system disease | - | Mammals, Fish | 0.4 | KE:1115 | Increase, Reactive oxygen species |
| KE:406 | decreased, Fertility | ||||||
| AOP:498 | Increased LCN2/iron complex leading to neurological disorders | Nervous system disease | - | Homo sapiens | 0.5 | KE:2150 | Neurological disorder |
| KE:191 | Neuronal dysfunction | ||||||
| AOP:499 | Activation of MEK-ERK1/2 leads to deficits in learning and cognition via disrupted neurotransmitter release | Developmental disorder of mental health | - | Rattus norvegicus, Mus musculus, Homo sapiens | 0.5 | KE:1339 | Increase, intracellular calcium |
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:500 | Activation of MEK-ERK1/2 leads to deficits in learning and cognition via ROS and apoptosis | Developmental disorder of mental health | - | Rattus norvegicus, Mus musculus, Homo sapiens | 0.57 | KE:1339 | Increase, intracellular calcium |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:1262 | Apoptosis | ||||||
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:501 | Excessive iron accumulation leading to neurological disorders | Nervous system disease | - | Homo sapiens | 0.5 | KE:1392 | Oxidative Stress |
| KE:2150 | Neurological disorder | ||||||
| AOP:504 | SULT1E1 inhibition leading to uterine adenocarcinoma via increased estrogen availability at target organ level | Unclassified | - | Mammals | 0.67 | KE:1065 | Activation, estrogen receptor alpha |
| KE:2251 | Estradiol availability, increased | ||||||
| AOP:521 | Essential element imbalance leads to reproductive failure via oxidative stress | Unclassified | - | Murinae gen. sp. | 0.71 | KE:2206 | Increased, histomorphological alteration of testis |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:1392 | Oxidative Stress | ||||||
| KE:1758 | Impaired, Spermatogenesis | ||||||
| KE:2147 | Decreased, Viable Offspring | ||||||
| AOP:533 | Retinoic acid receptor antagonism during neurodevelopment leading to impaired learning and memory | Developmental disorder of mental health | - | 0.17 | KE:341 | Impairment, Learning and memory | |
| AOP:534 | Succinate dehydrogenase (SDH) inhibition leads to cancer through oxidative stress | Cancer | - | Vertebrates | 0.5 | KE:1392 | Oxidative Stress |
| KE:885 | Increase, Cancer | ||||||
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:535 | Binding and activation of GPER leading to learning and memory impairments | Developmental disorder of mental health | - | Mouse, Human | 0.56 | KE:389 | Increased, Intracellular Calcium overload |
| KE:1392 | Oxidative Stress | ||||||
| KE:2233 | Decreased, ERαβ heterodimers | ||||||
| KE:341 | Impairment, Learning and memory | ||||||
| KE:1262 | Apoptosis | ||||||
| AOP:539 | Decreased Sodium/Potassium ATPase activity leads to Heart failure | Cardiovascular system disease | - | Fish | 0.29 | KE:2261 | Decreased, blood plasma volume |
| KE:1535 | Heart failure | ||||||
| AOP:546 | Succinate dehydrogenase inactivation leads to cancer through hypoxic-like mechanisms | Cancer | - | Human and other cells in culture | 0.2 | KE:885 | Increase, Cancer |
| AOP:550 | Increased LMNA gene mutation leading to heart failure | Cardiovascular system disease | - | Human, Mouse, Rat | 0.4 | KE:2066 | Altered Signaling Pathways |
| KE:1535 | Heart failure | ||||||
| AOP:552 | Inhibiton of L-Type Calcium Channels leading to heart failure via QT interval prolongation and Torsades de Pointes (TdP) | Cardiovascular system disease | - | Human, Rat, Mouse | 0.17 | KE:1535 | Heart failure |
| AOP:553 | Inhibition of Voltage-gated sodium channels (Na⁺ channels) leading to heart failure | Cardiovascular system disease | - | Human, Rodents, Dogs, Pigs, Insects, Fish | 0.25 | KE:1535 | Heart failure |
| AOP:555 | Inhibition, Ether-a-go-go (ERG) Voltage-Gated Potassium Channel leading to heart failure | Cardiovascular system disease | - | Human and other cells in culture, Dogs, Rat, Guinea pig, Rabbits, Zebrafish | 0.2 | KE:1535 | Heart failure |
| AOP:556 | Decreased Na/K ATPase activity leading to heart failure | Cardiovascular system disease | - | 0.33 | KE:389 | Increased, Intracellular Calcium overload | |
| KE:1535 | Heart failure | ||||||
| AOP:558 | Phosphodiesterase inhibition leading to heart failure | Cardiovascular system disease | - | Human and other cells in culture, Rodents, Dog, Pig, Zebrafish | 0.33 | KE:389 | Increased, Intracellular Calcium overload |
| KE:1535 | Heart failure | ||||||
| AOP:561 | Aromatase induction leading to estrogen receptor alpha activation via increased estradiol | Unclassified | - | Vertebrates | 0.8 | KE:2294 | Plasma estradiol, increased |
| KE:1065 | Activation, estrogen receptor alpha | ||||||
| KE:1076 | Increased, circulating estrogen levels | ||||||
| KE:2251 | Estradiol availability, increased | ||||||
| AOP:569 | Decreased DNA methylation of FAM50B/PTCHD3 leading to IQ loss of children via PI3K-Akt pathway | Developmental disorder of mental health | - | 0.33 | KE:1115 | Increase, Reactive oxygen species | |
| KE:2121 | decreased, Intellectual Quotient |
| AOP Identifier | AOP Title | AO Classification | OECD Status | Taxonomic applicability | Coverage Score ⓘ The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints. | KE Identifier | KE Name |
|---|---|---|---|---|---|---|---|
| AOP:8 | Upregulation of Thyroid Hormone Catabolism via Activation of Hepatic Nuclear Receptors, and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Nervous system disease | Under Development | Rat | 0.11 | KE:239 | Activation, Pregnane-X receptor, NR1l2 |
| AOP:16 | Acetylcholinesterase inhibition leading to acute mortality | Unclassified | Under Development | 0.14 | KE:12 | Acetylcholinesterase (AchE) Inhibition | |
| AOP:30 | Estrogen receptor antagonism leading to reproductive dysfunction | Unclassified | Under Review | Zebra danio, Fathead minnow, Medaka | 0.17 | KE:112 | Antagonism, Estrogen receptor |
| AOP:60 | NR1I2 (Pregnane X Receptor, PXR) activation leading to hepatic steatosis | Gastrointestinal system disease; Inherited metabolic disorder | - | 0.17 | KE:454 | Increased, Triglyceride formation | |
| KE:245 | Activation, PXR/SXR | ||||||
| AOP:111 | Decrease in androgen receptor activity leading to Leydig cell tumors (in rat) | Cancer; Reproductive system disease | - | Rattus norvegicus | 0.4 | KE:754 | Increased, Luteinizing hormone (LH) |
| KE:1614 | Decrease, androgen receptor activation | ||||||
| AOP:119 | Inhibition of thyroid peroxidase leading to follicular cell adenomas and carcinomas (in rat and mouse) | Cancer; Endocrine system disease | - | Rattus norvegicus, Mus musculus | 0.43 | KE:279 | Thyroperoxidase, Inhibition |
| KE:1023 | Increased, Thyroid-stimulating hormone (TSH) | ||||||
| KE:739 | Increase, Hypertrophy and proliferation (follicular cell) | ||||||
| AOP:159 | Thyroperoxidase inhibition leading to increased mortality via reduced anterior swim bladder inflation | Unclassified | WPHA/WNT Endorsed | Zebrafish, Fathead minnow | 0.12 | KE:279 | Thyroperoxidase, Inhibition |
| AOP:175 | Thyroperoxidase inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.25 | KE:279 | Thyroperoxidase, Inhibition |
| AOP:232 | NFE2/Nrf2 repression to steatosis | Gastrointestinal system disease; Inherited metabolic disorder | - | 0.12 | KE:1417 | NFE2/Nrf2 repression | |
| AOP:233 | Mu Opioid Receptor Agonism leading to Analgesia via K Channel Opening | Developmental disorder of mental health | - | 0.2 | KE:1425 | Mu Opioid Receptor Agonism | |
| AOP:234 | Mu Opioid Receptor Agonism leading to Analgesia via Ca Channel Inhibition | Developmental disorder of mental health | - | 0.2 | KE:1425 | Mu Opioid Receptor Agonism | |
| AOP:270 | Elevated ATP demand for detoxification and repair mechanisms leading to impaired locomotor activity | Unclassified | - | 0.12 | KE:10008 | Increased transcription for detoxification and repair mechanism | |
| AOP:271 | Inhibition of thyroid peroxidase leading to impaired fertility in fish | Unclassified | Under Development | Fish | 0.2 | KE:279 | Thyroperoxidase, Inhibition |
| AOP:281 | Acetylcholinesterase Inhibition Leading to Neurodegeneration | Nervous system disease | - | 0.2 | KE:12 | Acetylcholinesterase (AchE) Inhibition | |
| KE:389 | Increased, Intracellular Calcium overload | ||||||
| AOP:282 | Adverse outcome pathway on photochemical toxicity initiated by light exposure | Unclassified | Under Review | Human | 0.25 | KE:1115 | Increase, Reactive oxygen species |
| AOP:298 | Increase in reactive oxygen species (ROS) leading to human treatment-resistant gastric cancer via chronic ROS | Cancer; Gastrointestinal system disease | Under Review | Homo sapiens | 0.17 | KE:1115 | Increase, Reactive oxygen species |
| AOP:306 | Androgen receptor (AR) antagonism leading to short anogenital distance (AGD) in male (mammalian) offspring | Unclassified | Under Development | Rat, Human, Mouse | 0.5 | KE:1614 | Decrease, androgen receptor activation |
| KE:26 | Antagonism, Androgen receptor | ||||||
| AOP:312 | Acetylcholinesterase Inhibition leading to Acute Mortality via Impaired Coordination & Movement | Unclassified | - | 0.17 | KE:12 | Acetylcholinesterase (AchE) Inhibition | |
| AOP:314 | Binding to estrogen receptor (ER)-α in immune cells leading to exacerbation of systemic lupus erythematosus (SLE) | Immune system disease; Musculoskeletal system disease | Under Development | Homo sapiens | 0.2 | KE:1710 | Binding to estrogen receptor (ER)-α in immune cells |
| AOP:324 | Excessive reactive oxygen species leading to growth inhibition via oxidative DNA damage and cell death | Unclassified | - | Fish | 0.25 | KE:1115 | Increase, Reactive oxygen species |
| AOP:325 | Excessive reactive oxygen species leading to growth inhibition via lipid peroxidation and cell death | Unclassified | - | Fish | 0.25 | KE:1115 | Increase, Reactive oxygen species |
| AOP:326 | Excessive reactive oxygen species leading to growth inhibition via protein oxidation and cell death | Unclassified | - | Fish | 0.25 | KE:1115 | Increase, Reactive oxygen species |
| AOP:327 | Excessive reactive oxygen species production leading to mortality (1) | Unclassified | - | Daphnia magna | 0.4 | KE:1115 | Increase, Reactive oxygen species |
| KE:1769 | Increase, Body fluid overload | ||||||
| AOP:328 | Excessive reactive oxygen species production leading to mortality (2) | Unclassified | - | Daphnia magna | 0.4 | KE:1771 | Decrease, Adenosine triphosphate pool |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:329 | Excessive reactive oxygen species production leading to mortality (3) | Unclassified | - | Daphnia magna, Paracyclopina nana | 0.4 | KE:1771 | Decrease, Adenosine triphosphate pool |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:330 | Excessive reactive oxygen species production leading to mortality (4) | Unclassified | - | Daphnia magna | 0.4 | KE:1365 | Increase, Apoptosis |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:331 | Excessive reactive oxygen species leading to growth inhibition via oxidative DNA damage and reduced cell proliferation | Unclassified | - | Daphnia magna, Daphnia middendorffiana, Daphnia pulex, Daphnia pulicaria, Daphnia parvula | 0.33 | KE:1821 | Decrease, Cell proliferation |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:332 | Excessive reactive oxygen species leading to growth inhibition via lipid peroxidation and reduced cell proliferation | Unclassified | - | 0.4 | KE:1821 | Decrease, Cell proliferation | |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:333 | Excessive reactive oxygen species leading to growth inhibition via uncoupling of oxidative phosphorylation | Unclassified | - | 0.6 | KE:1771 | Decrease, Adenosine triphosphate pool | |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:1821 | Decrease, Cell proliferation | ||||||
| AOP:344 | Androgen receptor (AR) antagonism leading to nipple retention (NR) in male (mammalian) offspring | Unclassified | Under Development | 0.5 | KE:1614 | Decrease, androgen receptor activation | |
| KE:26 | Antagonism, Androgen receptor | ||||||
| AOP:363 | Thyroperoxidase inhibition leading to altered visual function via altered retinal layer structure | Unclassified | Under Review | Zebrafish | 0.12 | KE:279 | Thyroperoxidase, Inhibition |
| AOP:364 | Thyroperoxidase inhibition leading to altered visual function via decreased eye size | Unclassified | Under Development | 0.12 | KE:279 | Thyroperoxidase, Inhibition | |
| AOP:365 | Thyroperoxidase inhibition leading to altered visual function via altered photoreceptor patterning | Unclassified | Under Development | 0.12 | KE:279 | Thyroperoxidase, Inhibition | |
| AOP:372 | Androgen receptor antagonism leading to testicular cancer | Endocrine system disease; Reproductive system disease; Cancer | - | 0.6 | KE:1614 | Decrease, androgen receptor activation | |
| KE:26 | Antagonism, Androgen receptor | ||||||
| KE:1616 | Malformation, cryptorchidism - maldescended testis | ||||||
| AOP:411 | Oxidative stress Leading to Decreased Lung Function | Respiratory system disease | - | Homo sapiens | 0.25 | KE:1392 | Oxidative Stress |
| AOP:424 | Oxidative stress Leading to Decreased Lung Function via CFTR dysfunction | Respiratory system disease | - | Human | 0.17 | KE:1392 | Oxidative Stress |
| AOP:425 | Oxidative Stress Leading to Decreased Lung Function via Decreased FOXJ1 | Respiratory system disease | - | Human | 0.17 | KE:1392 | Oxidative Stress |
| AOP:438 | reactive oxygen species generation leading to increased cardiovascular morbidity and mortality | Cardiovascular system disease | - | 0.17 | KE:1392 | Oxidative Stress | |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:440 | Hypothalamus estrogen receptors activity suppression leading to ovarian cancer via ovarian epithelial cell hyperplasia | Benign neoplasm; Endocrine system disease; Reproductive system disease; Reproductive system disease; Cancer; Endocrine system disease | Under Development | Human, Rat, Mice | 0.56 | KE:1047 | Increased, secretion of GnRH from hypothalamus |
| KE:1046 | Suppression, Estrogen receptor (ER) activity | ||||||
| KE:1973 | Increased, estrogens | ||||||
| KE:1052 | Hyperplasia, ovarian epithelium | ||||||
| KE:1076 | Increased, circulating estrogen levels | ||||||
| AOP:444 | Ionizing radiation leads to reduced reproduction in Eisenia fetida via reduced spermatogenesis and cocoon hatchability | Unclassified | - | 0.44 | KE:1392 | Oxidative Stress | |
| KE:1194 | Increase, DNA damage | ||||||
| KE:1365 | Increase, Apoptosis | ||||||
| KE:1798 | Decreased spermatogenesis | ||||||
| AOP:446 | PM-related Adverse outcome pathway frameworks on various systems | Respiratory system disease | - | 0.25 | KE:1115 | Increase, Reactive oxygen species | |
| KE:1392 | Oxidative Stress | ||||||
| KE:1194 | Increase, DNA damage | ||||||
| KE:149 | Increase, Inflammation | ||||||
| KE:1262 | Apoptosis | ||||||
| AOP:448 | ROS, inflammation, and activation of nAChR lead to increased incidence of cardiovascular morbidity and mortality | Cardiovascular system disease | - | 0.12 | KE:1392 | Oxidative Stress | |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:450 | Inhibition of AChE and activation of CYP2E1 leading to sensory axonal peripheral neuropathy and mortality | Nervous system disease | - | Rattus norvegicus, Mus musculus, Homo sapiens | 0.29 | KE:1392 | Oxidative Stress |
| KE:12 | Acetylcholinesterase (AchE) Inhibition | ||||||
| AOP:453 | Reactive oxygen species and subsequent oxidative stress lead to increased incidence of digestive morbidity and mortality in the general population | Gastrointestinal system disease | - | 0.15 | KE:1392 | Oxidative Stress | |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:469 | Reactive oxygen speicies overproduction leading to increased digestive morbidity and mortality in generation population | Gastrointestinal system disease | - | 0.15 | KE:1392 | Oxidative Stress | |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:477 | Androgen receptor (AR) antagonism leading to hypospadias in male (mammalian) offspring | Physical disorder | - | 0.67 | KE:1614 | Decrease, androgen receptor activation | |
| KE:26 | Antagonism, Androgen receptor | ||||||
| AOP:507 | Nrf2 inhibition leading to vascular disrupting effects via inflammation pathway | Cardiovascular system disease | - | Mouse, Zebrafish, Human | 0.33 | KE:1392 | Oxidative Stress |
| KE:1417 | NFE2/Nrf2 repression | ||||||
| AOP:508 | Nrf2 inhibition leading to vascular disrupting effects through activating HIF1α, Semaphorin 6A, and Dll4-Notch pathway | Cardiovascular system disease | - | Mouse, Zebrafish, Human | 0.14 | KE:1417 | NFE2/Nrf2 repression |
| AOP:509 | Nrf2 inhibition leading to vascular disrupting effects through activating apoptosis signal pathway and mitochondrial dysfunction | Cardiovascular system disease | - | 0.43 | KE:1392 | Oxidative Stress | |
| KE:1417 | NFE2/Nrf2 repression | ||||||
| KE:1365 | Increase, Apoptosis | ||||||
| AOP:511 | The AOP framework on ROS-mediated oxidative stress induced vascular disrupting effects | Cardiovascular system disease | - | Human, Mouse, Zebrafish | 0.19 | KE:1392 | Oxidative Stress |
| KE:2172 | Activated Wnt/Frizzled pathway | ||||||
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:517 | Pregnane X Receptor (PXR) activation leads to liver steatosis | Gastrointestinal system disease; Inherited metabolic disorder | - | Vertebrates | 0.4 | KE:291 | Accumulation, Triglyceride |
| KE:239 | Activation, Pregnane-X receptor, NR1l2 | ||||||
| AOP:523 | Retinoic acid receptor agonism during neurodevelopment leading to microcephaly | Congenital nervous system abnormality; Nervous system disease | - | 0.2 | KE:2201 | Agonism, Retinoic acid receptor | |
| AOP:532 | Retinoic acid receptor agonism during cerebellar development leading to impaired locomotor function | Unclassified | - | 0.4 | KE:2229 | Cerebellar neuronal differentiation. Decreased | |
| KE:2201 | Agonism, Retinoic acid receptor | ||||||
| AOP:536 | Estrogen receptor agonism leading to reduced survival and population growth due to renal failure | Unclassified | - | 0.17 | KE:111 | Agonism, Estrogen receptor | |
| AOP:537 | Estrogen receptor agonism leads to reduced fecundity via increased vitellogenin in the liver | Unclassified | - | 0.4 | KE:364 | Impaired development of, Reproductive organs | |
| KE:111 | Agonism, Estrogen receptor | ||||||
| AOP:540 | Oxidative Stress in the Fish Ovary Leads to Reproductive Impairment via Reduced Vitellogenin Production | Unclassified | - | 0.44 | KE:1392 | Oxidative Stress | |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells | ||||||
| KE:1262 | Apoptosis | ||||||
| AOP:541 | Excessive ROS generation leading to increased incidence of vascular calcification by VSMC phenotype switching | Cardiovascular system disease | - | 0.15 | KE:1392 | Oxidative Stress | |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:545 | Activation, Pregnane-X receptor, NR1l2 leads to increased plasma low-density lipoprotein (LDL) cholesterol via increased cholesterol synthesis | Unclassified | - | Mammals | 0.2 | KE:239 | Activation, Pregnane-X receptor, NR1l2 |
| AOP:548 | Activation, Pregnane-X receptor, NR1l2 leads to increased plasma low-density lipoprotein (LDL) cholesterol via increased PCSK9 protein expression | Unclassified | - | Mammals | 0.2 | KE:239 | Activation, Pregnane-X receptor, NR1l2 |
| AOP:559 | Inhibition of acetylcholinesterase (AChE) leading to arrhythmias | Symptom | - | Human and other cells in culture, Rattus norvegicus, Dogs, Sus scrofa, Zebrafish, Insecta sp. BOLD:AAN5199 | 0.2 | KE:12 | Acetylcholinesterase (AchE) Inhibition |
| AOP Identifier | AOP Title | AO Classification | OECD Status | Taxonomic applicability | Coverage Score ⓘ The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints. | KE Identifier | KE Name |
|---|---|---|---|---|---|---|---|
| AOP:19 | Androgen receptor antagonism leading to adverse effects in the male foetus (mammals) | Reproductive system disease | - | 0.8 | KE:337 | N/A, Impairment of reproductive capacity | |
| KE:310 | Alteration, Wnt pathway | ||||||
| KE:26 | Antagonism, Androgen receptor | ||||||
| KE:240 | Feminisation or incomplete development, Primary and accessory male sex organs | ||||||
| AOP:42 | Inhibition of Thyroperoxidase and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive disorder | WPHA/WNT Endorsed | Human, Rat, Mouse | 0.25 | KE:279 | Thyroperoxidase, Inhibition |
| KE:402 | Cognitive function, decreased | ||||||
| AOP:118 | Chronic cytotoxicity leading to hepatocellular adenomas and carcinomas (in mouse and rat) | Cancer; Gastrointestinal system disease | - | Mus musculus, Rattus norvegicus | 0.75 | KE:719 | Increase, hepatocellular adenomas and carcinomas |
| KE:786 | Increase, Cytotoxicity (hepatocytes) | ||||||
| KE:787 | Increase, Regenerative cell proliferation (hepatocytes) | ||||||
| AOP:167 | Early-life estrogen receptor activity leading to endometrial carcinoma in the mouse. | Reproductive system disease; Cancer | - | Mouse, Homo sapiens | 1.0 | KE:1070 | Increased, adenosquamous carcinomas of endometrium |
| KE:1069 | Increased, Hyperplasia (glandular epithelial cells of endometrium) | ||||||
| KE:1067 | Proliferation/Clonal Expansion, aberrant basal cells | ||||||
| KE:1065 | Activation, estrogen receptor alpha | ||||||
| KE:1064 | prepubertal increase, Estrogen receptor (ER) activity | ||||||
| KE:1066 | Promotion, SIX-1 postive basal-type progenitor cells | ||||||
| KE:1068 | squamous metaplasia, aberrant basal cells | ||||||
| AOP:269 | Elevated ATP demand for detoxification and repair mechanisms leading to impaired growth and development | Unclassified | - | 0.33 | KE:10008 | Increased transcription for detoxification and repair mechanism | |
| KE:10013 | Impaired growth and development | ||||||
| AOP:288 | Inhibition of 17α-hydrolase/C 10,20-lyase (Cyp17A1) activity leads to birth reproductive defects (cryptorchidism) in male (mammals) | Endocrine system disease | - | Human, Rat | 0.5 | KE:1609 | Inhibition, Cytochrome P450 enzyme (CYP17A1) activity |
| KE:1614 | Decrease, androgen receptor activation | ||||||
| KE:1690 | Decrease, circulating testosterone levels | ||||||
| KE:1616 | Malformation, cryptorchidism - maldescended testis | ||||||
| AOP:293 | Increased DNA damage leading to increased risk of breast cancer | Genetic disease; Thoracic disease; Cancer | Under Development | Rattus rattus, Mus musculus | 0.33 | KE:1194 | Increase, DNA damage |
| KE:1193 | N/A, Breast Cancer | ||||||
| KE:1182 | Increase, Cell Proliferation (Epithelial Cells) | ||||||
| AOP:300 | Thyroid Receptor Antagonism and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive disorder | Under Development | Human, Mouse | 0.4 | KE:1656 | Antagonism, Thyroid Receptor |
| KE:402 | Cognitive function, decreased | ||||||
| AOP:345 | Androgen receptor (AR) antagonism leading to decreased fertility in females | Endocrine system disease; Reproductive system disease; Reproductive system disease | Under Development | Mammals | 0.5 | KE:1614 | Decrease, androgen receptor activation |
| KE:26 | Antagonism, Androgen receptor | ||||||
| KE:406 | decreased, Fertility | ||||||
| AOP:392 | Decreased fibrinolysis and activated bradykinin system leading to hyperinflammation | Unclassified | Under Development | Humans | 0.4 | KE:1866 | Fibrinolysis, decreased |
| KE:1868 | Hyperinflammation | ||||||
| AOP:405 | Organo-Phosphate Chemicals induced inhibition of AChE leading to impaired cognitive function | Cognitive disorder | - | Rattus norvegicus, Mus musculus, Homo sapiens | 0.4 | KE:12 | Acetylcholinesterase (AchE) Inhibition |
| KE:402 | Cognitive function, decreased | ||||||
| AOP:423 | Toxicological mechanisms of hepatocyte apoptosis through the PARP1 dependent cell death pathway | Unclassified | - | 0.5 | KE:1194 | Increase, DNA damage | |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:1817 | Apoptotic cell death | ||||||
| AOP:445 | Estrogen Receptor Alpha Agonism leads to Impaired Reproduction | Reproductive system disease | - | 0.38 | KE:1991 | Impaired, Reproduction | |
| KE:1065 | Activation, estrogen receptor alpha | ||||||
| KE:1989 | Impaired, Oocyte maturation and ovulation | ||||||
| AOP:447 | Kidney failure induced by inhibition of mitochondrial electron transfer chain through apoptosis, inflammation and oxidative stress pathways | Urinary system disease | - | 0.42 | KE:1392 | Oxidative Stress | |
| KE:759 | Increased, Kidney Failure | ||||||
| KE:1365 | Increase, Apoptosis | ||||||
| KE:1633 | Increase in inflammation | ||||||
| KE:1917 | Altered gene expression, NRF2 dependent antioxidant pathway | ||||||
| AOP:463 | The AOP framwork on silica nanopariticles induced hepatoxicity | Gastrointestinal system disease | - | 0.45 | KE:1115 | Increase, Reactive oxygen species | |
| KE:1392 | Oxidative Stress | ||||||
| KE:2034 | liver dysfunction | ||||||
| KE:149 | Increase, Inflammation | ||||||
| KE:1262 | Apoptosis | ||||||
| AOP:472 | DNA adduct formation leading to kidney failure | Urinary system disease | - | 0.67 | KE:1825 | Increase, Cell death | |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:1392 | Oxidative Stress | ||||||
| KE:1194 | Increase, DNA damage | ||||||
| KE:759 | Increased, Kidney Failure | ||||||
| KE:149 | Increase, Inflammation | ||||||
| AOP:485 | Thyroid hormone antagonism leading to impaired oligodendrocyte maturation during development and subsequent decreased cognition | Cognitive disorder | - | Human | 0.29 | KE:1656 | Antagonism, Thyroid Receptor |
| KE:402 | Cognitive function, decreased | ||||||
| AOP:488 | Increased reactive oxygen species production leading to decreased cognitive function | Cognitive disorder | - | Human | 0.43 | KE:1392 | Oxidative Stress |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:402 | Cognitive function, decreased | ||||||
| AOP:493 | ERa inactivation alters AT expansion and functions and leads to insulin resistance and metabolically unhealthy obesity | Acquired metabolic disease | - | Mus musculus, Homo sapiens | 0.4 | KE:2126 | Estrogen receptor alpha inactivation |
| KE:2129 | Metabolically unhealthy Obesity | ||||||
| KE:2125 | Increased fat mass | ||||||
| KE:1633 | Increase in inflammation | ||||||
| AOP:497 | ERa inactivation alters mitochondrial functions and insulin signalling in skeletal muscle and leads to insulin resistance and metabolic syndrome | Inherited metabolic disorder; Disease of metabolism | - | 0.5 | KE:1392 | Oxidative Stress | |
| KE:2145 | Metabolic syndrome | ||||||
| KE:2126 | Estrogen receptor alpha inactivation | ||||||
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:503 | Activation of uterine estrogen receptor-alfa leading to endometrial adenocarcinoma, via epigenetic modulation | Reproductive system disease; Cancer | Under Review | Human, Mouse | 0.83 | KE:2152 | Epigenetic modification process |
| KE:2154 | Uterine adenocarcinoma (endometrioid adenocarcinoma Type I) | ||||||
| KE:1065 | Activation, estrogen receptor alpha | ||||||
| KE:1896 | Genomic instability | ||||||
| KE:772 | Increase, Hyperplasia (glandular epithelial cells of endometrium) | ||||||
| AOP:505 | Reactive Oxygen Species (ROS) formation leads to cancer via inflammation pathway | Cancer | - | Human, Mouse, Rat | 0.8 | KE:1392 | Oxidative Stress |
| KE:885 | Increase, Cancer | ||||||
| KE:149 | Increase, Inflammation | ||||||
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:513 | Reactive Oxygen (ROS) formation leads to cancer via Peroxisome proliferation-activated receptor (PPAR) pathway | Cancer | - | Human, Mouse, Rat | 0.4 | KE:885 | Increase, Cancer |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:520 | Retinoic acid receptor agonism during neurodevelopment leading to impaired learning and memory | Developmental disorder of mental health | - | Mouse, Rat, Human | 0.6 | KE:2201 | Agonism, Retinoic acid receptor |
| KE:2204 | Altered brain morphology | ||||||
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:525 | Reduced oligodendrocyte differentiation during neurodevelopment leading to impaired learning and memory | Developmental disorder of mental health | - | 0.38 | KE:1656 | Antagonism, Thyroid Receptor | |
| KE:2115 | Altered, cholesterol metabolism | ||||||
| KE:2220 | Antagonism, Glucocorticoid hormone receptor | ||||||
| KE:341 | Impairment, Learning and memory | ||||||
| KE:2217 | Binding of antagonist to glucocorticoid hormone receptor |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.